Table 3 Single linear regression analysis for ln [TRACP-5b/iPTH]

Age, years

0.018

0.016

0.003, 0.032

Female sex

0.152

0.353

−0.171, 0.476

BMI, kg/m²

−0.042

0.026

−0.080, − 0.005

Chronic HD vintage, years

− 0.005

0.639

− 0.027, 0.017

 Heparin

(base)

(base)

(base)

 LMWH

− 0.359

0.194

−0.905, 0.186

 Nafamostat

0.373

0.287

−0.317, 1.063

 Diabetic nephropathy

(base)

(base)

(base)

 Nephrosclerosis

−0.041

0.854

−0.479, 0.397

 Glomerulonephritis

−0.046

0.831

−0.470, 0.379

 Others

0.156

0.516

−0.320, 0.633

Diabetes

−0.096

0.569

−0.431, 0.278

Ischemic heart disease

−0.085

0.647

−0.453, 0.283

Cerebrovascular disease

−0.294

0.171

−0.718, 0.129

CaSR agonist use

−0.532

0.001

−0.840, − 0.225

 None

(base)

(base)

(base)

 Cinacalcet/ Evocalcet

−0.450

0.004

−0.757, − 0.143

 Etelcalcetide (i.v.)

−1.290

< 0.001

− 1.953, − 0.625

VDRA use

− 0.744

0.009

− 1.301, − 0.187

 None

(base)

(base)

(base)

 Alfacalcidol/ Falecalcitriol

−0.467

0.098

− 1.021, 0.087

 Calcitriol (i.v.)

−1.013

0.001

−1.588, − 0.437

 Maxacalcitol (i.v.)

− 1.021

0.002

− 1.650, − 0.392

P binder use

− 0.041

0.856

− 0.490, 0.407

 None

(base)

(base)

(base)

 Ca-containing

0.278

0.380

−0.348, 0.905

 Non-Ca containing

−0.166

0.482

−0.632, 0.300

 Both

0.090

0.739

−0.444, 0.624

Steroid use history

−0.212

0.391

−0.699, 0.276

β blocker use

−0.165

0.310

−0.486, 0.156

Statin use

−0.129

0.483

−0.492, 0.234

Warfarin use

0.432

0.184

−0.209, 1.073

Bisphosphonate use

−0.120

0.615

−0.594, 0.353

Fracture history

0.185

0.427

−0.274, 0.644

Ankle-brachial index

−0.115

0.831

−1.176. 0.947

Alb, g/dL

−0.251

0.344

−0.774, 0.272

cCa, mg/dL

0.319

0.007

0.090. 0.548

P, mg/dL

−0.173

0.018

−0.316, − 0.031

ln [25(OH)D]

− 0.275

0.208

− 0.705, 0.155

ln [1, 25(OH)₂D]

0.250

0.044

0.007, 0.493

ln [BAP]

0.195

0.282

−0.163, 0.553